Management of diabetes webinar 1 - assessment answers

1. Which TWO of the following are consequences of not escalating treatment early in type 2 diabetes?
a. A vicious metabolic memory, which is not reversed by intensive glycaemic control
c. Accumulation of a bad glycaemic legacy, which drives risk of complications

2. In the context of diabetes (glycaemia), what is therapeautic inertia?
b. Failure to commence or intensify therapy despite failing to achieve the agreed upon HbA1c goal

3. What is the biggest contributor to therapeutic inertia in diabetes?
b. Provider-level barriers

4. Which TWO of the following are system-level barriers that contribute to therapeutic inertia in diabetes?
a. Healthcare access and costs
c. Limited availability of new medications

5. It is important to establish an indvidualised HbA1c target as part of the patient-centred approach to glycaemic management in type 2 diabetes. Which of the following patients should be treated most aggressively, aiming for a low HbA1c level?
c. A young patient with an absence of comorbidities

6. What is recommended by the American Diabetes Association and European Association for the Study of Diabetes for first-line glycaemic control in type 2 diabetes?
b. Metformin and comprehensive lifestyle modification

7. The choice of second-line medication to be added to metformin is based on patient preference and clinical characteristics. According to guidelines from the American Diabetes Association and European Association for the Study of Diabetes, what is the preferred glucose-lowering medication(s) to add to metformin for those with established atherosclerotic cardiovascular disease?
b. GLP-1 receptor agonist or SGLT2 inhibitor

8. Which TWO of the following statements regarding weight loss in diabetes are correct?
c. There is a linear relationship between weight loss and HbA1c reduction
e. Weight management within primary care can achieve remission of type 2 diabetes